Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD

Recruiting now · Phase 3

Conditions studied: Alzheimer Disease, Neurofibrillary Tangle

In brief

The goal of this clinical trial is to evaluate the efficacy and safety of XTR006 injection PET visual reading in detecting brain neurofibrillary tangles (NFTs) in elderly subjects with Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), and cognitively normal individuals. The main question it aims to answer is: • What is the sensitivity and specificity of XTR006 PET visual reading results compared to the truth standard across MCI, AD, and cognitively normal subjects? Participants will: * Receive XTR006 injection * Undergo PET/CT scanning

Key facts

Study ID

NCT07115238

Run by

Sinotau Pharmaceutical Group

People needed

354

Starts

2024-11-20

Expected to finish

2026-06-30

Last updated by the study team

2025-08-11

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Inclusion Criteria for All Subjects:
• Male or female subjects aged ≥50 years.
• Able to tolerate both PET and MRI examinations.
• Must use contraceptive measures during the study period and for 6 months after study completion.
• Written informed consent must be obtained before any assessment is performed.
• Inclusion Criteria for Cognitively Normal Subjects:
• CDR (Clinical Dementia Rating) score of 0. 2）MMSE (Mini-Mental State Examination) score ≥28. 3）Negative visual reading result on brain Aβ-PET imaging.
• Inclusion Criteria for Subjects with MCI:
• Meet the core clinical criteria for MCI due to AD according to 2011 NIA-AA (National Institute on Aging-Alzheimer's Association) standards
• Positive visual reading result on brain Aβ-PET imaging
• Inclusion Criteria for Subjects with AD:
• Meet the specific clinical phenotype criteria for typical AD according to 2014 International Working Group (IWG)-2 standards:
• Positive visual reading result on brain Aβ-PET imaging.

You may not qualify if…

• Diagnosis of atypical AD, frontotemporal lobar degeneration (FTLD), Lewy body dementia, or other types of dementia.
• Current significant psychiatric illness with symptoms that prevent completion of imaging procedures.
• MRI-confirmed structural brain abnormalities, such as large stroke or intracranial mass lesions.
• Claustrophobia.
• History of alcohol abuse or drug abuse/dependence.
• Allergy to the study drug or any of its components.
• Women who are currently breastfeeding.

Where it is running

• Chinese PLA General Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.